Most rare subtypes of cutaneous lymphoma display variable CD30 expression. Analysis of the German Cutaneous Lymphoma Network.
2021
CD30, also known as tumor necrosis factor receptor 8 (TNF-R 8), was primarily called Ki-1 and is a cell surface molecule which has first been described from a group of pathologists from Kiel in 1982.1 CD30 can be targeted with the drug brentuximab-vedotin (BV), which is approved for relapsed or refractory CD30+ cutaneous T-cell lymphoma (CTCL) including primary cutaneous anaplastic large cell lymphoma and CD30+ mycosis fungoides and Sezary syndrome.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
8
References
0
Citations
NaN
KQI